CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Ipswich Investment Management Co. Inc.

Ipswich Investment Management Co. Inc. lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,288 shares of the company’s stock after buying an additional 750 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in CRISPR Therapeutics were worth $995,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. increased its position in shares of CRISPR Therapeutics by 158.7% during the third quarter. Blue Trust Inc. now owns 3,844 shares of the company’s stock worth $181,000 after purchasing an additional 2,358 shares in the last quarter. Eastern Bank purchased a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $70,000. International Assets Investment Management LLC purchased a new stake in CRISPR Therapeutics in the third quarter valued at approximately $1,825,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 15.9% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 40,568 shares of the company’s stock valued at $1,906,000 after acquiring an additional 5,567 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of CRISPR Therapeutics by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock worth $146,000 after acquiring an additional 545 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $47.91 on Friday. The stock has a fifty day moving average price of $42.25 and a 200 day moving average price of $46.06. The stock has a market cap of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.03 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of recent research reports. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Morgan Stanley upped their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Stifel Nicolaus reduced their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.